Bevacizumab/Doxorubicin/Radiation for Sarcoma

This study is currently recruiting participants.
Verified March 2014 by Massachusetts General Hospital
Sponsor:
Information provided by (Responsible Party):
Edwin Choy, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01746238
First received: December 5, 2012
Last updated: March 26, 2014
Last verified: March 2014

December 5, 2012
March 26, 2014
March 2013
January 2015   (final data collection date for primary outcome measure)
Determine MTD of bevacizumab+doxorubicin+radiation [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
To determine the maximum tolerated dose of bevacizumab when administered concurrently with metronomic doxorubicin and radiation therapy for resectable intermediate and high-grade soft tissue sarcomas
Same as current
Complete list of historical versions of study NCT01746238 on ClinicalTrials.gov Archive Site
  • Pathologic response rate [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To determine the pathologic response rate for neoadjuvant bevacizumab, metronomic doxorubicin, and radiation therapy (trimodality therapy) for resectable intermediate and high-risk soft tissue sarcoma
  • gene expression signatures [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To confirm gene expression signatures as biomarkers for response to trimodality therapy
  • Obtain preliminary data overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To obtain preliminary data regarding overall survival with trimodality therapy
  • Microvessel density [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To confirm microvessel density as biomarkers for response to trimodality therapy
  • Obtain preliminary data regarding local control [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To obtain preliminary data regarding local control with trimodality therapy
  • Obtain preliminary data regarding distant control [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To obtain preliminary data regarding distant control with trimodality therapy
  • Obtain preliminary data disease-free survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To obtain preliminary data regarding disease-free survival with trimodality therapy
Same as current
Not Provided
Not Provided
 
Bevacizumab/Doxorubicin/Radiation for Sarcoma
Phase I Trial of Bevacizumab, Metronomic Doxorubicin and Radiation Therapy for Resectable Soft Tissue Sarcoma

The main purpose of this study is to test the safety, tolerability, maximum tolerated dose, and effectiveness of bevacizumab in combination with chemotherapy and radiation therapy.

Because bevacizumab is not considered standard therapy for sarcomas, it can only be given to subjects with sarcoma who are enrolled in this research study and may only be administered under the direction of doctors who are investigators in this research study.

This study is being done because sarcomas can recur after surgical resection (surgery for removal of the tumor), radiation therapy and chemotherapy. This recurrence can occur in the same location as the original tumor or in distant sites such as the lung. Thus better treatments are needed.

This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational drug, combination of drugs, or combination of drugs with radiation. Phase I studies also try to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the combination of drugs and radiation is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not approved bevacizumab with doxorubicin and radiation for your type of cancer.

In order to determine if patients are eligible for this study patients will undergo some screening procedures, including a medical history, physical examination, performance status, assessment of tumor, chest CT scan, blood tests, urine test, electrocardiogram and echocardiogram. Patients will also undergo blood tests and a tumor biopsy to look for markers for your particular type of cancer.

If it is determined that patients are eligible to be in the study they will need to have a central venous line (CVL), peripherally inserted central catheter (PICC), or portacath placement. Doxorubicin administration requires a central venous line, peripherally inserted central catheter (PICC) or portacath to be placed to allow continuous infusion of this drug.

Since the investigators are looking for the highest tolerable dose of the study drug, bevacizumab, that can be administered safely without severe or unmanageable side effects in participants that have sarcoma, not everyone who participates in this research study will receive the same dose of the study drug. The dose patients get will depend on the number of participants who have been enrolled in the study and how well they have tolerated their doses. The dose of doxorubicin and radiation therapy will be the same for all subjects throughout the study.

Bevacizumab will be given as an intravenous infusion (IV). The first infusion will take about 90 minutes. All other bevacizumab infusions will take either 60 or 30 minutes, if tolerated. The first infusion will be given on a Monday (excluding holidays). Patients will receive the second infusion 2 weeks later and then every 2 weeks after that for a total of 3 doses.

Doxorubicin will be given as an intravenous infusion (IV). It will be given through a port via an infusion pump about the size of a large wallet that can fit into a front-pack or "fanny-pack" around their waist. This pump will be connected to their body. The nurses in the infusion room will start the pump and disconnect it after 4 days. The first bolus infusion take will be given 1-2 hours after their first bevacizumab infusion and will take about 30 minutes. This will be followed by a continuous IV infusion of doxorubicin over 4 days. The first bolus infusion will be given on a Monday (excluding holidays) and the continuous infusion will go until Thursday. Patients will receive a second bolus infusion followed by a 4 day continuous infusion every week for 5 weeks.

Patients will begin radiation therapy after their first bevacizumab and doxorubicin infusion on Monday (excluding holidays). Radiation therapy will be delivered five days per week (Monday through Friday-excluding holidays) over a period of 6 weeks. This is done as an outpatient procedure. Each 2-week period will be considered a separate treatment cycle. Patients will be treated with radiation therapy for a maximum of 3 cycles (6 weeks).

The following tests and procedures will be done during the study during weeks 2, 4 and 6 and before surgery: a medical history, physical examination, performance status, blood tests, urine tests and assessment for any side effects. Patients will have additional CT scans of their chest and tumor before surgery. An ECG will be repeated at this time.

A surgeon will evaluate the tumor by reviewing radiologic studies before study treatment to determine if surgical removal is possible. After patients complete study treatment with radiation therapy and bevacizumab, a surgeon will repeat the evaluation of the tumor by reviewing radiologic studies to determine if surgical removal is still possible. Patients will have surgery 6-7 weeks after they finish radiation therapy.

Patients will have additional radiation therapy if the research doctor thinks that some cancer cells may have been left in their body in the area where the tumor was removed. The radiation may be given while patients are in surgery or about two weeks after the surgery. This will be determined by the surgeon and or radiation oncologist.

Patients will be in this research study for about 3 months. After the last dose of the study drug the investigators would like to keep track of their medical condition for 10 years. The investigators would like to do this by calling patients by telephone once a year to see how they are doing. Keeping in touch with them and checking their condition every year helps the investigators look at the long term effects of the research study.

Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Sarcoma
  • Drug: Bevacizumab
    Intravenous infusion, every 2 weeks, 3 doses total
    Other Name: Avastin
  • Drug: Doxorubicin
    Intravenous infusion, bolus infusion followed by 4 day continuous infusion, every week for 5 weeks
    Other Name: Adriamycin
  • Radiation: Radiation Therapy
    Daily, Monday-Friday, for 6 weeks
    Other Name: XRT
Experimental: Treatment Arm
Bevacizumab, metronomic doxorubicin and radiation therapy
Interventions:
  • Drug: Bevacizumab
  • Drug: Doxorubicin
  • Radiation: Radiation Therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
18
January 2016
January 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Primary soft tissue sarcoma or isolated local recurrent sarcoma without prior radiation
  • Histologically intermediate- or high-grade soft tissue sarcoma
  • Determined by an expert sarcoma surgeon to have resectable disease located on the upper extremity, lower extremity, trunk, retroperitoneum or pelvis
  • Primary tumor must be at least 5 cm in maximal diameter or an isolated local recurrence of any size

Exclusion Criteria:

  • Metastatic disease
  • Pregnant or breastfeeding
  • Immunotherapy, chemotherapy, experimental therapy or radiotherapy within 4 weeks of first day of study drug dosing
  • Previously received doxorubicin, any other anthracycline chemotherapy or bevacizumab
  • Major surgery within 4 weeks before first day of study drug dosing
  • Uncontrolled intercurrent illness
  • History of myocardial infarction, acute coronary syndromes, coronary angioplasty or coronary artery stenting within previous 6 months
  • Other medical or psychiatric conditions that may interfere with study participation
  • Known hypercoagulable disorder
  • Known history of deep vein thrombosis or pulmonary embolus
  • Presence of bleeding diathesis or coagulopathy
  • Current use of therapeutic anticoagulants
Both
18 Years and older
No
Contact: Barbara Anderson, RN 617-643-2427 BANDERSON15@PARTNERS.ORG
Contact: McDowell Natasha 617-643-1940 nmcdowell@partners.org
United States
 
NCT01746238
12-396
Yes
Edwin Choy, MD, Massachusetts General Hospital
Massachusetts General Hospital
Not Provided
Principal Investigator: Edwin Choy, MD Massachusetts General Hospital
Massachusetts General Hospital
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP